FDA Beats Alvogen Suit Over Xifaxan Skinny Label Rejection

A district court has ruled against an Alvogen subsidiary challenging the FDA’s rejection of its ANDA for a “skinny version” of Silax Pharmaceuticals’ blockbuster irritable bowel syndrome drug Xifaxan (rifaximin).
Source: Drug Industry Daily